Breaking News

Over a week ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Initiation
Avrobio initiated with a Buy at BTIG » 16:30
06/14/21
06/14
16:30
06/14/21
16:30
AVRO

Avrobio

$9.59 /

+0.06 (+0.63%)

BTIG analyst Yun Zhong…

BTIG analyst Yun Zhong initiated coverage of Avrobio with a Buy rating and $23 price target. Zhong sees good prospects from the entire pipeline, adding that he remains confident in lentiveral gene therapy's safety. The analyst sees "significant" long-term potential from the company's lentiviral platform.

ShowHide Related Items >><<
AVRO Avrobio
$9.59 /

+0.06 (+0.63%)

AVRO Avrobio
$9.59 /

+0.06 (+0.63%)

05/27/21 Needham
Needham starts Avrobio with a Buy on differentiated platform
05/27/21 Needham
Avrobio initiated with a Buy at Needham
05/04/21 Wells Fargo
Avrobio price target lowered to $36 from $58 at Wells Fargo
05/04/21 Mizuho
Avrobio price target lowered to $28 from $43 at Mizuho
AVRO Avrobio
$9.59 /

+0.06 (+0.63%)

  • 20
    Nov
Initiation
Needham starts Avrobio with a Buy on differentiated platform » 07:28
05/27/21
05/27
07:28
05/27/21
07:28
AVRO

Avrobio

$8.01 /

-0.15 (-1.84%)

As previously reported,…

As previously reported, Needham analyst Gil Blum initiated coverage of Avrobio with a Buy rating and $28 price target. The analyst sees the company's Lentivirus based gene therapy as being differentiated from both standard-of-care enzyme replacement therapy and emerging adeno-associated virus based gene therapy in the treatment of lysosomal storage disorders, or LSDs. Blum adds that .AvroBio has active clinical programs in 3 LSDs with potential for over $2B in peak sales.

ShowHide Related Items >><<
AVRO Avrobio
$8.01 /

-0.15 (-1.84%)

AVRO Avrobio
$8.01 /

-0.15 (-1.84%)

05/27/21 Needham
Avrobio initiated with a Buy at Needham
05/04/21 Wells Fargo
Avrobio price target lowered to $36 from $58 at Wells Fargo
05/04/21 Mizuho
Avrobio price target lowered to $28 from $43 at Mizuho
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
AVRO Avrobio
$8.01 /

-0.15 (-1.84%)

  • 20
    Nov
Initiation
Avrobio initiated with a Buy at Needham » 06:11
05/27/21
05/27
06:11
05/27/21
06:11
AVRO

Avrobio

$8.01 /

-0.15 (-1.84%)

Needham analyst Gil Blum…

Needham analyst Gil Blum initiated coverage of Avrobio with a Buy rating and $28 price target.

ShowHide Related Items >><<
AVRO Avrobio
$8.01 /

-0.15 (-1.84%)

AVRO Avrobio
$8.01 /

-0.15 (-1.84%)

05/04/21 Wells Fargo
Avrobio price target lowered to $36 from $58 at Wells Fargo
05/04/21 Mizuho
Avrobio price target lowered to $28 from $43 at Mizuho
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
AVRO Avrobio
$8.01 /

-0.15 (-1.84%)

  • 20
    Nov
Over a month ago
Earnings
Avrobio reports Q1 EPS (65c), consensus (77c) » 07:06
05/13/21
05/13
07:06
05/13/21
07:06
AVRO

Avrobio

$8.79 /

+0.3 (+3.53%)

As of March 31, 2021,…

As of March 31, 2021, AVROBIO had $233.0 million in cash and cash equivalents, as compared to $259.7 million in cash and cash equivalents as of Dec. 31, 2020. Based on the company's current operating plan, AVROBIO expects its cash and cash equivalents as of March 31, 2021, will enable the company to fund its operating expenses and capital expenditure requirements into the first quarter of 2023. .During the first quarter, we met with the U.S. Food and Drug Administration to discuss the regulatory path for AVR-RD-01, our investigational gene therapy for Fabry disease. We plan to engage with FDA in the second half of 2021 to seek feedback on our proposal for a registration trial," said Geoff MacKay, president and CEO of AVROBIO. "In addition, we started the year with strong data updates from all three of our clinical programs - Fabry disease, Gaucher disease and cystinosis - at the WORLDSymposium. These data show sustained improvements across important biomarkers and functional metrics, which we believe support the potential of our lentiviral gene therapy platform to treat life-limiting lysosomal disorders. We have been gratified by the strong interest in our clinical trials, and we're pleased with our progress in enrolling and dosing new patients, including three patients dosed in just the last three months in our FAB-GT trial. As we advance AVR-RD-01, we plan to continue to execute across our pipeline, and we look forward to providing future updates."

ShowHide Related Items >><<
AVRO Avrobio
$8.79 /

+0.3 (+3.53%)

AVRO Avrobio
$8.79 /

+0.3 (+3.53%)

05/04/21 Wells Fargo
Avrobio price target lowered to $36 from $58 at Wells Fargo
05/04/21 Mizuho
Avrobio price target lowered to $28 from $43 at Mizuho
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
AVRO Avrobio
$8.79 /

+0.3 (+3.53%)

  • 20
    Nov
AVRO Avrobio
$8.79 /

+0.3 (+3.53%)

Recommendations
Avrobio price target lowered to $36 from $58 at Wells Fargo » 07:43
05/04/21
05/04
07:43
05/04/21
07:43
AVRO

Avrobio

/

+

Wells Fargo analyst Yanan…

Wells Fargo analyst Yanan Zhu lowered the firm's price target on Avrobio to $36 from $58 and keeps an Overweight rating on the shares following review of the regulatory update on the company's lead lentiviral gene therapy program AVR-RD-01 for Fabry disease. While the closing of the accelerated approval pathway for AVR-RD-01 is "disappointing," the analyst believes there should be no impact on the probability of success of the program. In addition, while the new development time line is longer versus accelerated approval path, Zhu notes that the newly anticipated phase 3 study is to have similar size, scope, and duration as the previously contemplated confirmatory trial, except for a two-quarter delay in study launch, which may be partially offset by Avrobio's efforts in mobilizing ex-U.S. sites.

ShowHide Related Items >><<
AVRO Avrobio
/

+

AVRO Avrobio
/

+

05/04/21 Mizuho
Avrobio price target lowered to $28 from $43 at Mizuho
04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/09/21 Barclays
Avrobio initiated with an Overweight at Barclays
AVRO Avrobio
/

+

  • 20
    Nov
AVRO Avrobio
/

+

Recommendations
Avrobio price target lowered to $28 from $43 at Mizuho » 06:38
05/04/21
05/04
06:38
05/04/21
06:38
AVRO

Avrobio

/

+

Mizuho analyst Difei Yang…

Mizuho analyst Difei Yang lowered the firm's price target on Avrobio to $28 from $43 and keeps a Buy rating on the shares after the company provided a regulatory update on the registration pathway for its lead gene therapy program in Fabry disease. The analyst now projects a potential regulatory approval in 2025, versus 2023 previously, for the lead Fabry program. While the delay is negative event for the company and weighed on the shares, there is a "silver lining here:" the registration pathway is now clearer with a validated primary endpoint, and Avrobio remains in the leading position among gene therapy programs with "strong" clinical data, says Yang.

ShowHide Related Items >><<
AVRO Avrobio
/

+

AVRO Avrobio
/

+

04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/09/21 Barclays
Avrobio initiated with an Overweight at Barclays
03/01/21 Stifel
Avrobio initiated with a Hold at Stifel
AVRO Avrobio
/

+

  • 20
    Nov
AVRO Avrobio
/

+

Hot Stocks
Avrobio provides update on investigational AVR-RD-01 for Fabry disease » 07:11
05/03/21
05/03
07:11
05/03/21
07:11
AVRO

Avrobio

$11.69 /

+0.08 (+0.69%)

AVROBIO provided an…

AVROBIO provided an update on its regulatory plans for AVR-RD-01, the first investigational lentiviral gene therapy for Fabry disease. This update follows a recent U.S. regulatory development for Fabry disease therapies, as well as AVROBIO's receipt of minutes from the company's Type B meeting with the U.S. Food and Drug Administration on March 31, On March 11, 2021, approximately three weeks before the company's End-of-Phase 1 meeting, FDA granted full approval of Fabrazyme(R) more than 18 years after the enzyme replacement therapy received accelerated approval on the basis of a surrogate endpoint: reduction of GL-3 (also referred to as Gb3) inclusions in biopsied renal peritubular capillaries. The conversion of Fabrazyme to full approval opens a new pathway for full approval of ERTs based on this surrogate endpoint, which AVROBIO believes could potentially apply to investigational AVR-RD-01. In addition, the conversion of Fabrazyme to full approval limits the accelerated approval pathways available for new therapies to treat Fabry disease. As a result, AVROBIO can no longer pursue an accelerated approval pathway for AVR-RD-01 with the FAB-GT trial as currently designed, and instead intends to discuss with FDA a registration trial with a primary efficacy endpoint of clearance of GL-3/Gb3 inclusions in biopsied renal PTCs as the basis for full approval. "We believe we have a potential new path to pursue full approval for investigational AVR-RD-01 as a first-line therapy for Fabry disease by conducting a single, head-to-head registration trial versus Fabrazyme using a kidney biopsy surrogate endpoint similar to our FAB-GT Phase 2 trial, where we have seen 100% and 87% substrate reductions at one year post-gene therapy in the two patients with evaluable kidney biopsies," said Geoff MacKay, CEO and president of AVROBIO. "We plan to design a registration trial with a scope, size and duration comparable to other gene therapy trials." In its FDA briefing book, which was submitted to FDA prior to Fabrazyme's full approval, the company sought an accelerated approval pathway by expanding the FAB-GT Phase 2 clinical trial and conducting an additional confirmatory trial. The revised regulatory plan anticipates retaining the two-study approach with a similar overall requirement in terms of scope, size and duration. The company plans to engage FDA to discuss and agree upon its revised approach, with the goal of initiating the registration trial in mid-2022. Although FDA guidance provides that a surrogate endpoint in a particular clinical development program should not be assumed to be appropriate for use in a different program, AVROBIO believes this recent development could potentially apply to investigational AVR-RD-01, a gene therapy designed to facilitate the production of functional enzyme by the patient's own stem cells after a one-time treatment with the therapeutic gene.

ShowHide Related Items >><<
AVRO Avrobio
$11.69 /

+0.08 (+0.69%)

AVRO Avrobio
$11.69 /

+0.08 (+0.69%)

04/28/21 Stifel
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel
03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/09/21 Barclays
Avrobio initiated with an Overweight at Barclays
03/01/21 Stifel
Avrobio initiated with a Hold at Stifel
AVRO Avrobio
$11.69 /

+0.08 (+0.69%)

  • 20
    Nov
AVRO Avrobio
$11.69 /

+0.08 (+0.69%)

Recommendations
Protalix, Sanofi updates may signal headwinds for Avrobio, Amicus, says Stifel » 10:01
04/28/21
04/28
10:01
04/28/21
10:01
PLX

Protalix

$3.52 /

-2.32 (-39.73%)

, SNY

Sanofi

$52.87 /

+1.37 (+2.66%)

, AVRO

Avrobio

$11.31 /

-0.32 (-2.75%)

, FIXX

Homology Medicines

$6.86 /

-0.03 (-0.44%)

, FOLD

Amicus

$10.14 /

+0.05 (+0.50%)

Stifel analyst Dae Gon Ha…

Stifel analyst Dae Gon Ha said Protalix (PLX) receiving a complete response letter from the FDA for the biologics license application seeking accelerated approval of pegunigalsidase alfa and Sanofi's (SNY) avalglucosidase alfa getting a PDUFA extension may raise investor questions again about the FDA's stance on new investigational drugs. Given the target indications of these two drugs, he wonders if the FDA is applying a more stringent set of expectations in rare diseases where an approved standard of care exists and, if so, Ha questions if Avrobio (AVRO), Homology Medicines (FIXX) and Amicus (FOLD) may "face some headwinds in the near-to-medium term."

ShowHide Related Items >><<
SNY Sanofi
$52.87 /

+1.37 (+2.66%)

PLX Protalix
$3.52 /

-2.32 (-39.73%)

FOLD Amicus
$10.14 /

+0.05 (+0.50%)

FIXX Homology Medicines
$6.86 /

-0.03 (-0.44%)

AVRO Avrobio
$11.31 /

-0.32 (-2.75%)

PLX Protalix
$3.52 /

-2.32 (-39.73%)

12/31/20 H.C. Wainwright
Protalix data underscore value proposition for PRX-102, says H.C. Wainwright
SNY Sanofi
$52.87 /

+1.37 (+2.66%)

04/06/21 Barclays
Sanofi price target raised to EUR 85 from EUR 80 at Barclays
02/23/21 BofA
BofA adds Heineken and IAG, removes Roche and Sanofi from Europe 1 list
02/10/21 Morgan Stanley
Sanofi price target raised to EUR 104 from EUR 101 at Morgan Stanley
02/05/21 Piper Sandler
Piper reiterates Overweight on Kymera after Sanofi capital markets day
AVRO Avrobio
$11.31 /

-0.32 (-2.75%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/09/21 Barclays
Avrobio initiated with an Overweight at Barclays
03/01/21 Stifel
Avrobio initiated with a Hold at Stifel
02/17/21 Mizuho
Avrobio selloff on Bluebird news a buying opportunity, says Mizuho
FIXX Homology Medicines
$6.86 /

-0.03 (-0.44%)

03/01/21 Stifel
Homology Medicines initiated with a Hold at Stifel
03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
FOLD Amicus
$10.14 /

+0.05 (+0.50%)

04/14/21 Cantor Fitzgerald
Amicus upgraded to Overweight from Neutral at Cantor Fitzgerald
04/13/21 Cantor Fitzgerald
Amicus upgraded to Overweight from Neutral at Cantor Fitzgerald
03/01/21 Stifel
Amicus initiated with a Hold at Stifel
02/12/21
Fly Intel: Top five analyst downgrades
SNY Sanofi
$52.87 /

+1.37 (+2.66%)

FOLD Amicus
$10.14 /

+0.05 (+0.50%)

FIXX Homology Medicines
$6.86 /

-0.03 (-0.44%)

AVRO Avrobio
$11.31 /

-0.32 (-2.75%)

  • 07
    Apr
  • 12
    Feb
  • 20
    Nov
SNY Sanofi
$52.87 /

+1.37 (+2.66%)

FOLD Amicus
$10.14 /

+0.05 (+0.50%)

SNY Sanofi
$52.87 /

+1.37 (+2.66%)

PLX Protalix
$3.52 /

-2.32 (-39.73%)

FOLD Amicus
$10.14 /

+0.05 (+0.50%)

FIXX Homology Medicines
$6.86 /

-0.03 (-0.44%)

AVRO Avrobio
$11.31 /

-0.32 (-2.75%)

FOLD Amicus
$10.14 /

+0.05 (+0.50%)

Conference/Events
Chardan to hold a virtual summit » 04:55
04/27/21
04/27
04:55
04/27/21
04:55
OXBDF

Oxford Biomedica

$15.25 /

-0.165 (-1.07%)

, AVRO

Avrobio

$11.80 /

+0.475 (+4.19%)

, CTLT

Catalent

$115.74 /

+0.91 (+0.79%)

, FIXX

Homology Medicines

$6.88 /

+0.1 (+1.47%)

, FRLN

Freeline

$12.61 /

+0.08 (+0.64%)

, LZAGY

Lonza

$60.74 /

-0.365 (-0.60%)

, MBIO

Mustang Bio

$3.29 /

+0.13 (+4.12%)

, MGTX

MeiraGTx

$14.51 /

+1 (+7.40%)

, ORTX

Orchard Therapeutics

$6.26 /

+0.1 (+1.62%)

, PASG

Passage Bio

$17.99 /

+1.07 (+6.32%)

, QURE

uniQure

$34.97 /

+2.72 (+8.43%)

, RCKT

Rocket Pharmaceuticals

$46.35 /

+1.55 (+3.46%)

, RGNX

Regenxbio

$35.48 /

+1.13 (+3.29%)

, SLDB

Solid Biosciences

$5.19 /

+0.095 (+1.86%)

, TSHA

Taysha Gene Therapies

$24.35 /

+1.6 (+7.03%)

5th Annual Genetic…

5th Annual Genetic Medicines Manufacturing Virtual Summit to be held on April 26-27.

ShowHide Related Items >><<
TSHA Taysha Gene Therapies
$24.35 /

+1.6 (+7.03%)

SLDB Solid Biosciences
$5.19 /

+0.095 (+1.86%)

RGNX Regenxbio
$35.48 /

+1.13 (+3.29%)

RCKT Rocket Pharmaceuticals
$46.35 /

+1.55 (+3.46%)

QURE uniQure
$34.97 /

+2.72 (+8.43%)

PASG Passage Bio
$17.99 /

+1.07 (+6.32%)

OXBDF Oxford Biomedica
$15.25 /

-0.165 (-1.07%)

ORTX Orchard Therapeutics
$6.26 /

+0.1 (+1.62%)

MGTX MeiraGTx
$14.51 /

+1 (+7.40%)

MBIO Mustang Bio
$3.29 /

+0.13 (+4.12%)

LZAGY Lonza
$60.74 /

-0.365 (-0.60%)

FRLN Freeline
$12.61 /

+0.08 (+0.64%)

FIXX Homology Medicines
$6.88 /

+0.1 (+1.47%)

CTLT Catalent
$115.74 /

+0.91 (+0.79%)

AVRO Avrobio
$11.80 /

+0.475 (+4.19%)

OXBDF Oxford Biomedica
$15.25 /

-0.165 (-1.07%)

10/09/20 RBC Capital
Oxford Biomedica still a strong investment proposition, says RBC Capital
07/27/20 RBC Capital
Oxford Biomedica initiated with an Outperform at RBC Capital
07/27/20 RBC Capital
Oxford Biomedica initiated with an Outperform at RBC Capital
AVRO Avrobio
$11.80 /

+0.475 (+4.19%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/09/21 Barclays
Avrobio initiated with an Overweight at Barclays
03/01/21 Stifel
Avrobio initiated with a Hold at Stifel
02/17/21 Mizuho
Avrobio selloff on Bluebird news a buying opportunity, says Mizuho
CTLT Catalent
$115.74 /

+0.91 (+0.79%)

04/07/21 Jefferies
Catalent pact with Moderna removes potential overhang, says Jefferies
03/02/21 Argus
Catalent price target raised to $140 from $130 at Argus
02/03/21 UBS
Catalent price target raised to $135 from $115 at UBS
02/03/21 RBC Capital
Catalent price target raised to $137 from $125 at RBC Capital
FIXX Homology Medicines
$6.88 /

+0.1 (+1.47%)

03/01/21 Stifel
Homology Medicines initiated with a Hold at Stifel
03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
FRLN Freeline
$12.61 /

+0.08 (+0.64%)

03/22/21 Mizuho
Freeline initiated with a Buy at Mizuho
03/01/21 Stifel
Freeline initiated with a Buy at Stifel
11/25/20 Redburn
Freeline initiated with a Neutral at Redburn
09/01/20 Evercore ISI
Freeline initiated with an Outperform at Evercore ISI
LZAGY Lonza
$60.74 /

-0.365 (-0.60%)

02/23/21 JPMorgan
Lonza upgraded to Overweight from Neutral at JPMorgan
02/16/21 Deutsche Bank
Lonza price target raised to CHF 680 from CHF 630 at Deutsche Bank
02/10/21 Berenberg
Lonza price target raised to CHF 690 from CHF 410 at Berenberg
02/02/21 Morgan Stanley
Lonza price target raised to CHF 645 from CHF 630 at Morgan Stanley
MBIO Mustang Bio
$3.29 /

+0.13 (+4.12%)

12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
10/27/20 B. Riley
Mustang Bio selloff not related to fundamentals, says B. Riley Securities
10/26/20 Oppenheimer
Oppenheimer sees case study supporting MB-105 development in prostate cancer
10/26/20 H.C. Wainwright
Mustang Bio's Phase 1 data in PSCA-mCRPC 'encouraging,' says H.C. Wainwright
MGTX MeiraGTx
$14.51 /

+1 (+7.40%)

02/16/21 Chardan
MeiraGTx called a Top Pick for 2021 at Chardan
12/17/20 Chardan
Chardan boosts MeiraGTx target to $55, say buy shares 'now'
12/17/20 Piper Sandler
Piper says MeiraGTx not getting credit for RIX gene therapy that 'clearly works'
10/22/20 RBC Capital
MeiraGTx initiated with an Outperform at RBC Capital
ORTX Orchard Therapeutics
$6.26 /

+0.1 (+1.62%)

03/02/21 JPMorgan
Orchard Therapeutics assumed with an Overweight at JPMorgan
03/01/21 Stifel
Orchard Therapeutics initiated with a Buy at Stifel
02/18/21 Goldman Sachs
Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs
PASG Passage Bio
$17.99 /

+1.07 (+6.32%)

04/05/21 Morgan Stanley
Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley
03/08/21 Chardan
Passage Bio price target raised to $45 from $35 at Chardan
03/04/21 Citi
Citi remains buyer of Passage Bio into first clinical data
03/04/21 Goldman Sachs
Passage Bio upgraded to Buy from Neutral at Goldman Sachs
QURE uniQure
$34.97 /

+2.72 (+8.43%)

04/26/21 Chardan
Chardan sees 'stock momentum' for uniQure after clinical hold lift
04/26/21 Credit Suisse
uniQure assumed with an Outperform at Credit Suisse
04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Mizuho
uniQure upgraded to Buy on favorable risk/reward at Mizuho
RCKT Rocket Pharmaceuticals
$46.35 /

+1.55 (+3.46%)

04/01/21 SVB Leerink
Rocket Pharmaceuticals price target raised to $66 from $61 at SVB Leerink
03/22/21 William Blair
Rocket data shows durable impact for PKD, says William Blair
03/01/21 Stifel
Rocket Pharmaceuticals initiated with a Buy at Stifel
RGNX Regenxbio
$35.48 /

+1.13 (+3.29%)

02/09/21 Morgan Stanley
Sarepta denied motion to dismiss 'Wilson Wolf' case, says Morgan Stanley
01/20/21 RBC Capital
Regenxbio price target raised to $50 from $42 at RBC Capital
01/06/21 Chardan
Regenxbio named top 2021 pick with $100 target at Chardan
SLDB Solid Biosciences
$5.19 /

+0.095 (+1.86%)

03/16/21 Chardan
Solid Biosciences price target raised to $20 from $12.50 at Chardan
03/16/21
Fly Intel: Top five analyst upgrades
03/16/21 SVB Leerink
Solid Biosciences upgraded to Outperform at SVB Leerink
03/16/21 SVB Leerink
Solid Biosciences upgraded to Outperform from Market Perform at SVB Leerink
TSHA Taysha Gene Therapies
$24.35 /

+1.6 (+7.03%)

04/12/21 Chardan
Taysha Gene Therapies price target raised to $67.50 from $60 at Chardan
03/04/21 Chardan
Taysha Gene Therapies price target raised to $60 from $45 at Chardan
02/23/21 William Blair
William Blair starts Taysha with Outperform, $46 fair-value estimate
02/23/21 William Blair
William Blair starts Taysha Gene Therapies with Outperform on positive FDA draft
TSHA Taysha Gene Therapies
$24.35 /

+1.6 (+7.03%)

SLDB Solid Biosciences
$5.19 /

+0.095 (+1.86%)

RGNX Regenxbio
$35.48 /

+1.13 (+3.29%)

RCKT Rocket Pharmaceuticals
$46.35 /

+1.55 (+3.46%)

QURE uniQure
$34.97 /

+2.72 (+8.43%)

PASG Passage Bio
$17.99 /

+1.07 (+6.32%)

ORTX Orchard Therapeutics
$6.26 /

+0.1 (+1.62%)

MGTX MeiraGTx
$14.51 /

+1 (+7.40%)

MBIO Mustang Bio
$3.29 /

+0.13 (+4.12%)

FIXX Homology Medicines
$6.88 /

+0.1 (+1.47%)

CTLT Catalent
$115.74 /

+0.91 (+0.79%)

AVRO Avrobio
$11.80 /

+0.475 (+4.19%)

  • 07
    Apr
  • 19
    Mar
  • 22
    Jan
  • 08
    Jan
  • 10
    Dec
  • 23
    Nov
  • 20
    Nov
  • 19
    Nov
  • 24
    Sep
  • 07
    Aug
  • 11
    Jun
  • 11
    Jun
CTLT Catalent
$115.74 /

+0.91 (+0.79%)

SLDB Solid Biosciences
$5.19 /

+0.095 (+1.86%)

RGNX Regenxbio
$35.48 /

+1.13 (+3.29%)

RCKT Rocket Pharmaceuticals
$46.35 /

+1.55 (+3.46%)

QURE uniQure
$34.97 /

+2.72 (+8.43%)

PASG Passage Bio
$17.99 /

+1.07 (+6.32%)

FIXX Homology Medicines
$6.88 /

+0.1 (+1.47%)

CTLT Catalent
$115.74 /

+0.91 (+0.79%)

AVRO Avrobio
$11.80 /

+0.475 (+4.19%)

PASG Passage Bio
$17.99 /

+1.07 (+6.32%)

Conference/Events
Chardan to hold a virtual summit » 09:30
04/26/21
04/26
09:30
04/26/21
09:30
OXBDF

Oxford Biomedica

$15.42 /

+0.21 (+1.38%)

, AVRO

Avrobio

$11.37 /

+0.03 (+0.26%)

, CTLT

Catalent

$114.83 /

+1.52 (+1.34%)

, FIXX

Homology Medicines

$6.78 /

+0.04 (+0.59%)

, FRLN

Freeline

$12.53 /

-0.11 (-0.87%)

, LZAGY

Lonza

$61.10 /

+0.03 (+0.05%)

, MBIO

Mustang Bio

$3.16 /

-0.03 (-0.94%)

, MGTX

MeiraGTx

$13.59 /

-0.51 (-3.62%)

, ORTX

Orchard Therapeutics

$6.17 /

+0.18 (+3.01%)

, PASG

Passage Bio

$16.92 /

-0.82 (-4.62%)

, QURE

uniQure

$32.25 /

-0.66 (-2.01%)

, RCKT

Rocket Pharmaceuticals

$44.80 /

+0.35 (+0.79%)

, RGNX

Regenxbio

$34.25 /

-0.48 (-1.38%)

, SLDB

Solid Biosciences

$5.09 /

+0.195 (+3.98%)

, TSHA

Taysha Gene Therapies

$22.77 /

-0.35 (-1.51%)

5th Annual Genetic…

5th Annual Genetic Medicines Manufacturing Virtual Summit to be held on April 26-27.

ShowHide Related Items >><<
TSHA Taysha Gene Therapies
$22.77 /

-0.35 (-1.51%)

SLDB Solid Biosciences
$5.09 /

+0.195 (+3.98%)

RGNX Regenxbio
$34.25 /

-0.48 (-1.38%)

RCKT Rocket Pharmaceuticals
$44.80 /

+0.35 (+0.79%)

QURE uniQure
$32.25 /

-0.66 (-2.01%)

PASG Passage Bio
$16.92 /

-0.82 (-4.62%)

OXBDF Oxford Biomedica
$15.42 /

+0.21 (+1.38%)

ORTX Orchard Therapeutics
$6.17 /

+0.18 (+3.01%)

MGTX MeiraGTx
$13.59 /

-0.51 (-3.62%)

MBIO Mustang Bio
$3.16 /

-0.03 (-0.94%)

LZAGY Lonza
$61.10 /

+0.03 (+0.05%)

FRLN Freeline
$12.53 /

-0.11 (-0.87%)

FIXX Homology Medicines
$6.78 /

+0.04 (+0.59%)

CTLT Catalent
$114.83 /

+1.52 (+1.34%)

AVRO Avrobio
$11.37 /

+0.03 (+0.26%)

OXBDF Oxford Biomedica
$15.42 /

+0.21 (+1.38%)

10/09/20 RBC Capital
Oxford Biomedica still a strong investment proposition, says RBC Capital
07/27/20 RBC Capital
Oxford Biomedica initiated with an Outperform at RBC Capital
07/27/20 RBC Capital
Oxford Biomedica initiated with an Outperform at RBC Capital
AVRO Avrobio
$11.37 /

+0.03 (+0.26%)

03/10/21 Stifel
Stifel says Bluebird update on AML provides 'some relief' to other LV players
03/09/21 Barclays
Avrobio initiated with an Overweight at Barclays
03/01/21 Stifel
Avrobio initiated with a Hold at Stifel
02/17/21 Mizuho
Avrobio selloff on Bluebird news a buying opportunity, says Mizuho
CTLT Catalent
$114.83 /

+1.52 (+1.34%)

04/07/21 Jefferies
Catalent pact with Moderna removes potential overhang, says Jefferies
03/02/21 Argus
Catalent price target raised to $140 from $130 at Argus
02/03/21 UBS
Catalent price target raised to $135 from $115 at UBS
02/03/21 RBC Capital
Catalent price target raised to $137 from $125 at RBC Capital
FIXX Homology Medicines
$6.78 /

+0.04 (+0.59%)

03/01/21 Stifel
Homology Medicines initiated with a Hold at Stifel
03/01/21 Oppenheimer
Homology Medicines loses potential source of upside, says Oppenheimer
12/14/20 H.C. Wainwright
Homology Medicines transferred with Buy, $30 target at H.C. Wainwright
11/08/20 Oppenheimer
Homology Medicines selloff unjustified in wake of clinical PoC, says Oppenheimer
FRLN Freeline
$12.53 /

-0.11 (-0.87%)

03/22/21 Mizuho
Freeline initiated with a Buy at Mizuho
03/01/21 Stifel
Freeline initiated with a Buy at Stifel
11/25/20 Redburn
Freeline initiated with a Neutral at Redburn
09/01/20 Evercore ISI
Freeline initiated with an Outperform at Evercore ISI
LZAGY Lonza
$61.10 /

+0.03 (+0.05%)

02/23/21 JPMorgan
Lonza upgraded to Overweight from Neutral at JPMorgan
02/16/21 Deutsche Bank
Lonza price target raised to CHF 680 from CHF 630 at Deutsche Bank
02/10/21 Berenberg
Lonza price target raised to CHF 690 from CHF 410 at Berenberg
02/02/21 Morgan Stanley
Lonza price target raised to CHF 645 from CHF 630 at Morgan Stanley
MBIO Mustang Bio
$3.16 /

-0.03 (-0.94%)

12/23/20 B. Riley
Mustang Bio transferred with a Buy at B. Riley Securities
10/27/20 B. Riley
Mustang Bio selloff not related to fundamentals, says B. Riley Securities
10/26/20 Oppenheimer
Oppenheimer sees case study supporting MB-105 development in prostate cancer
10/26/20 H.C. Wainwright
Mustang Bio's Phase 1 data in PSCA-mCRPC 'encouraging,' says H.C. Wainwright
MGTX MeiraGTx
$13.59 /

-0.51 (-3.62%)

02/16/21 Chardan
MeiraGTx called a Top Pick for 2021 at Chardan
12/17/20 Chardan
Chardan boosts MeiraGTx target to $55, say buy shares 'now'
12/17/20 Piper Sandler
Piper says MeiraGTx not getting credit for RIX gene therapy that 'clearly works'
10/22/20 RBC Capital
MeiraGTx initiated with an Outperform at RBC Capital
ORTX Orchard Therapeutics
$6.17 /

+0.18 (+3.01%)

03/02/21 JPMorgan
Orchard Therapeutics assumed with an Overweight at JPMorgan
03/01/21 Stifel
Orchard Therapeutics initiated with a Buy at Stifel
02/18/21 Goldman Sachs
Orchard selloff on Bluebird Bio news overdone, says Goldman Sachs
PASG Passage Bio
$16.92 /

-0.82 (-4.62%)

04/05/21 Morgan Stanley
Regenxbio AAV9 patent challenged by Passage Bio, says Morgan Stanley
03/08/21 Chardan
Passage Bio price target raised to $45 from $35 at Chardan
03/04/21 Citi
Citi remains buyer of Passage Bio into first clinical data
03/04/21 Goldman Sachs
Passage Bio upgraded to Buy from Neutral at Goldman Sachs
QURE uniQure
$32.25 /

-0.66 (-2.01%)

04/26/21 Credit Suisse
uniQure assumed with an Outperform at Credit Suisse
04/01/21
Fly Intel: Top five analyst upgrades
04/01/21 Mizuho
uniQure upgraded to Buy on favorable risk/reward at Mizuho
04/01/21 Mizuho
uniQure upgraded to Buy from Neutral at Mizuho
RCKT Rocket Pharmaceuticals
$44.80 /

+0.35 (+0.79%)

04/01/21 SVB Leerink
Rocket Pharmaceuticals price target raised to $66 from $61 at SVB Leerink
03/22/21 William Blair
Rocket data shows durable impact for PKD, says William Blair
03/01/21 Stifel
Rocket Pharmaceuticals initiated with a Buy at Stifel
RGNX Regenxbio
$34.25 /

-0.48 (-1.38%)

02/09/21 Morgan Stanley
Sarepta denied motion to dismiss 'Wilson Wolf' case, says Morgan Stanley
01/20/21 RBC Capital
Regenxbio price target raised to $50 from $42 at RBC Capital
01/06/21 Chardan
Regenxbio named top 2021 pick with $100 target at Chardan
SLDB Solid Biosciences
$5.09 /

+0.195 (+3.98%)

03/16/21 Chardan
Solid Biosciences price target raised to $20 from $12.50 at Chardan
03/16/21
Fly Intel: Top five analyst upgrades
03/16/21 SVB Leerink
Solid Biosciences upgraded to Outperform at SVB Leerink
03/16/21 SVB Leerink
Solid Biosciences upgraded to Outperform from Market Perform at SVB Leerink
TSHA Taysha Gene Therapies
$22.77 /

-0.35 (-1.51%)

04/12/21 Chardan
Taysha Gene Therapies price target raised to $67.50 from $60 at Chardan
03/04/21 Chardan
Taysha Gene Therapies price target raised to $60 from $45 at Chardan
02/23/21 William Blair
William Blair starts Taysha with Outperform, $46 fair-value estimate
02/23/21 William Blair
William Blair starts Taysha Gene Therapies with Outperform on positive FDA draft
TSHA Taysha Gene Therapies
$22.77 /

-0.35 (-1.51%)

SLDB Solid Biosciences
$5.09 /

+0.195 (+3.98%)

RGNX Regenxbio
$34.25 /

-0.48 (-1.38%)

RCKT Rocket Pharmaceuticals
$44.80 /

+0.35 (+0.79%)

QURE uniQure
$32.25 /

-0.66 (-2.01%)

PASG Passage Bio
$16.92 /

-0.82 (-4.62%)

ORTX Orchard Therapeutics
$6.17 /

+0.18 (+3.01%)

MGTX MeiraGTx
$13.59 /

-0.51 (-3.62%)

MBIO Mustang Bio
$3.16 /

-0.03 (-0.94%)

FIXX Homology Medicines
$6.78 /

+0.04 (+0.59%)

CTLT Catalent
$114.83 /

+1.52 (+1.34%)

AVRO Avrobio
$11.37 /

+0.03 (+0.26%)

  • 07
    Apr
  • 19
    Mar
  • 22
    Jan
  • 08
    Jan
  • 10
    Dec
  • 23
    Nov
  • 20
    Nov
  • 19
    Nov
  • 24
    Sep
  • 07
    Aug
  • 11
    Jun
  • 11
    Jun
CTLT Catalent
$114.83 /

+1.52 (+1.34%)

SLDB Solid Biosciences
$5.09 /

+0.195 (+3.98%)

RGNX Regenxbio
$34.25 /

-0.48 (-1.38%)

RCKT Rocket Pharmaceuticals
$44.80 /

+0.35 (+0.79%)

QURE uniQure
$32.25 /

-0.66 (-2.01%)

PASG Passage Bio
$16.92 /

-0.82 (-4.62%)

FIXX Homology Medicines
$6.78 /

+0.04 (+0.59%)

CTLT Catalent
$114.83 /

+1.52 (+1.34%)

AVRO Avrobio
$11.37 /

+0.03 (+0.26%)

PASG Passage Bio
$16.92 /

-0.82 (-4.62%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.